Egis Pharmaceuticals Plc

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

7 Corporate Content #SupplierSpotlight, 2 Data Compilation #PharmaFlow, 31 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

53 All APIs, 2 USDMF, 17 CEP/COS, 5 JDMF, 4 KDMF, 2 NDC API, 2 VMF, 44 Listed APIs

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

100 FDF Dossiers, 17 Europe, 83 Listed Dossiers

KEY PRODUCTS

Abemaciclib, Atorvastatin, Chlorpromazine Hydrochloride, Dapagliflozin, Levomepromazine Maleate, Osimertinib Mesylate, Promethazine Hydrochloride, Ramipril, Ribociclib, Sacubitril-Valsartan

SERVICES

API Manufacturing, API & Drug Product Development

API Manufacturing
API & Drug Product Development
- 5 API Development

KEY SERVICES

CDMO for Small Molecules, Manufacturing of Intermediates & APIs, Highly Potent API Manufacturing, CDMO for Intermediates & APIs

INSPECTIONS & REGISTRATIONS

7 FDA, 25 EDQM, 1 GDUFA

Filters

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

FDF Product List 2025

Open PDF

Upload

API Product List 2025

Open PDF

Upload

APIs Under Development 2025

Pharma Services

GMP Certificate 2024

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey. NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region. Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.

Impressions: 1612

CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord). Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation.

Impressions: 8444

NEWS #PharmaBuzz

Egis Pharma And BME Partner To Advance Engineering Innovation

01 Sep 2025

// PRESS RELEASE

Egis Invests Over HUF 14 Billion in Körmend Site Development

28 Jul 2025

// PRESS RELEASE

Hungarian Pharma Giants May Begin Uzbekistan Production

24 Jun 2025

// PRESS RELEASE

Egis & the University of Szeged Expand Their Cooperation

05 Mar 2025

// PRESS RELEASE

Our project aimed at developing oncological active ingredients

24 Feb 2025

// PRESS RELEASE

Development Of High-Value Onco Drugs For Personalized Therapies

05 Feb 2025

// PRESS RELEASE

Contact Egis Pharmaceuticals Plc and get a quotation

Egis Pharmaceuticals Plc is a supplier offers 50 products (APIs, Excipients or Intermediates).

Find a price of Promethazine Hydrochloride bulk with DMF, CEP, JDMF offered by Egis Pharmaceuticals Plc

Find a price of Allopurinol bulk with CEP, JDMF offered by Egis Pharmaceuticals Plc

Find a price of Chlorpromazine Hydrochloride bulk with CEP, JDMF offered by Egis Pharmaceuticals Plc

Find a price of Ethacrynic Acid bulk with DMF, CEP offered by Egis Pharmaceuticals Plc

Find a price of Allopurinol bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Amlodipine Besylate bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Aripiprazole bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Bisoprolol Fumarate bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Carbidopa bulk with JDMF offered by Egis Pharmaceuticals Plc

Find a price of Carvedilol bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Duloxetine Hydrochloride bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Levomepromazine Maleate bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Methyldopa bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Quetiapine Hemifumarate bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Ramipril bulk with CEP offered by Egis Pharmaceuticals Plc

Find a price of Tofisopam bulk with JDMF offered by Egis Pharmaceuticals Plc

Find a price of Abemaciclib bulk offered by Egis Pharmaceuticals Plc

Find a price of Abrocitinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Acalabrutinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Alectinib Hydrochloride bulk offered by Egis Pharmaceuticals Plc

Find a price of Avapritinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Blarcamesine bulk offered by Egis Pharmaceuticals Plc

Find a price of Carbadox bulk offered by Egis Pharmaceuticals Plc

Find a price of Clomiphene Citrate bulk offered by Egis Pharmaceuticals Plc

Find a price of Crotamiton bulk offered by Egis Pharmaceuticals Plc

Find a price of Dapagliflozin Propanediol Monohydrate bulk offered by Egis Pharmaceuticals Plc

Find a price of Deucravacitinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Donepezil bulk offered by Egis Pharmaceuticals Plc

Find a price of Empagliflozin bulk offered by Egis Pharmaceuticals Plc

Find a price of Entrectinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Etrasimod bulk offered by Egis Pharmaceuticals Plc

Find a price of Fruquintinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Ketoprofen bulk offered by Egis Pharmaceuticals Plc

Find a price of Levocetirizine Dihydrochloride bulk offered by Egis Pharmaceuticals Plc

Find a price of Methoprene bulk offered by Egis Pharmaceuticals Plc

Find a price of Nifedipine bulk offered by Egis Pharmaceuticals Plc

Find a price of Nitrendipine bulk offered by Egis Pharmaceuticals Plc

Find a price of Osimertinib Mesylate bulk offered by Egis Pharmaceuticals Plc

Find a price of Ozanimod bulk offered by Egis Pharmaceuticals Plc

Find a price of Palbociclib bulk offered by Egis Pharmaceuticals Plc

Find a price of Pimavanserin Tartrate bulk offered by Egis Pharmaceuticals Plc

Find a price of Resmetirom bulk offered by Egis Pharmaceuticals Plc

Find a price of Ribociclib bulk offered by Egis Pharmaceuticals Plc

Find a price of Rivaroxaban bulk offered by Egis Pharmaceuticals Plc

Find a price of Sacubitril-Valsartan bulk offered by Egis Pharmaceuticals Plc

Find a price of Solriamfetol Hydrochloride bulk offered by Egis Pharmaceuticals Plc

Find a price of Tofisopam bulk offered by Egis Pharmaceuticals Plc

Find a price of Troriluzole bulk offered by Egis Pharmaceuticals Plc

Find a price of Upadacitinib bulk offered by Egis Pharmaceuticals Plc

Find a price of Venetoclax bulk offered by Egis Pharmaceuticals Plc